Curriculum · Nephrology and Urology
Gadolinium contrast in chronic kidney disease
What it is
The use of gadolinium contrast has been associated with acute kidney injury, and also with the development of nephrogenic systemic sclerosis in patients with stage 4 or 5 chronic kidney disease.
The threshold
Because of these risks, the FDA recommends avoiding gadolinium contrast in patients with a glomerular filtration rate below 30 mL/min/1.73 m2, as well as in patients with acute renal failure. Nephrogenic systemic sclerosis is the thing to be avoided, and avoiding the contrast is the only way given to avoid it.
So the two lines to hold are a GFR under 30 mL/min/1.73 m2, and acute renal failure at any GFR.
The worked case
A 64-year-old female with hypertension, diabetes mellitus, hyperlipidemia and chronic kidney disease has headaches escalating over the past 6 months, with double vision and ataxia. Her medications include lisinopril and atorvastatin. Her blood pressure is 144/64 mm Hg, and a basic metabolic panel is normal except for a creatinine level of 2.1 mg/dL against a normal of 0.6-1.1, and an estimated glomerular filtration rate of 26 mL/min/1.73 m2.
An MRI of the brain is indicated by the symptoms, and the answer is avoiding the use of gadolinium contrast, not finding a way to give it.
What does not make it safe
The risk of nephrogenic systemic sclerosis is not affected by blood pressure, medications, intravenous hydration, or pretreatment with n-acetylcysteine. Each of the three ways round the problem offered in that case is therefore wrong:
- Using gadolinium once the blood pressure is controlled to a goal systolic pressure below 130 mm Hg does not help
- Pretreating with n-acetylcysteine and intravenous normal saline does not help
- Stopping lisinopril 48 hours before the MRI does not help
There is no pretreatment that makes gadolinium safe in this setting; the contrast is left out.